Background:
HIV-1 envelope glycoproteins (Envs) mediate viral entry and are the sole target of neutralizing antibodies. Envs of most primary HIV-1 strains exist in a closed conformation and occasionally sample more open Env states. Thus, current knowledge guides immunogen design to mimic the closed Env conformation as the preferred target for eliciting broadly neutralizing antibodies (bnAbs) to block HIV-1 entry.
Methods:
We evaluated the conformational state of transmitted/founder (T/F) HIV-1 Envs on infectious virions by measuring HIV-1 sensitivity to: 1) antibodies that target internal epitopes, 2) bnAbs, 3) soluble CD4 (sCD4), and 4) exposure to cold. Recognition of soluble HIV-1 Envs (gp120) and surface-expressed Envs by antibodies was measured by ELISA and flow cytometry, respectively. We solved the cryo-EM structure of an unliganded T/F Envs (1059-SOSIP) at 3.6 Å resolution using a large data set and analyzed sub-class structures to estimate the heterogeneity of Env conformations.
Results:
We identified T/F HIV-1 Envs that are incompletely closed and sensitive to antibodies that target internal epitopes, to sCD4, and to cold exposure. A cryo-electron microscopy structure of unliganded, incompletely closed T/F Envs (1059-SOSIP), which is resistant to VRC01, at 3.6 Å resolution exhibits an asymmetric configuration of Env protomers with increased sampling of states with incompletely closed trimer apex. We further show a correlation between efficient neutralization of multiple Env conformations and increased antiviral breadth of CD4-binding site (CD4bs) bnAbs. In particular, N6 CD4bs bnAb, which uniquely recognizes different Env conformations, efficiently neutralizes 50% of the HIV-1 strains that were resistant to VRC01 and transmitted during the first-in-humans antibody-mediated prevention trial (HVTN 704). VRC01-resistant Envs are incompletely closed based on their sensitivity to cold and on partial sensitivity to antibodies targeting internal epitopes, which are typically occluded in tightly closed Envs. Most VRC01-resistant Envs retain the VRC01 epitope according to VRC01 binding to their gp120 subunit at concentrations that have no significant effect on virus entry, and they exhibit cross resistance to other CD4bs bnAbs that preferentially neutralize the closed Env conformation.
Conclusions:
Our findings refine current knowledge of Env conformational states and provide guidance for developing new strategies for bnAb immunotherapy and Env-based immunogen design.